This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, Z. Articles by Yamada, N. Search for Related Content PubMed PubMed Citation Articles by Chen, Z. Articles by Yamada, N. Related Collections Cardiovascular Pharmacology Gene expression Genetically altered mice Type 2 diabetes Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:372.)
© 2001 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice

Pleiotropic Effects on CD36 Expression and HDL

Zhong Chen; Shun Ishibashi; Stéphane Perrey; Jun-ichi Osuga; Takanari Gotoda; Tetsuya Kitamine; Yoshiaki Tamura; Hiroaki Okazaki; Naoya Yahagi; Yoko Iizuka; Futoshi Shionoiri; Ken Ohashi; Kenji Harada; Hitoshi Shimano; Ryozo Nagai; Nobuhiro Yamada

From the Departments of Metabolic Diseases (Z.C., S.I., S.P., J.-i.O., T.G., T.K., Y.T., H.O., N. Yahagi, Y.I., F.S., K.O., K.H., H.S., N. Yamada) and Cardiovascular Medicine (R.N.), Faculty of Medicine, University of Tokyo, Tokyo, Japan. Dr Yamada and Dr Shimano are presently at the Metabolism, Endocrinology and Atherosclerosis Section, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan.

Correspondence to Shun Ishibashi, MD, PhD, Department of Metabolic Diseases, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail ishibash-tky{at}umin.u-tokyo.ac.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Atherosclerotic coronary heart disease is a common complication of the insulin resistance syndrome that can occur with or without diabetes mellitus. Thiazolidinediones (TZDs), which are insulin-sensitizing antidiabetic agents, can modulate the development of atherosclerosis not only by changing the systemic metabolic conditions associated with insulin resistance but also by exerting direct effects on vascular wall cells that express peroxisome proliferator–activated receptor- (PPAR-), a nuclear receptor for TZDs. Here we show that troglitazone, a TZD, significantly inhibited fatty streak lesion formation in apolipoprotein E–knockout mice fed a high-fat diet (en face aortic surface lesion areas were 6.9±2.5% vs 12.7±4.7%, P<0.05; cross-sectional lesion areas were 191 974±102 911 µm² vs 351 738±175 597 µm², P<0.05; n=10). Troglitazone attenuated hyperinsulinemic hyperglycemia and increased high density lipoprotein cholesterol levels. In the aorta, troglitazone markedly increased the mRNA levels of CD36, a scavenger receptor for oxidized low density lipoprotein, presumably by upregulating its expression, at least in part, in the macrophage foam cells. These results indicate that troglitazone potently inhibits fatty streak lesion formation by modulating both metabolic extracellular environments and arterial wall cell functions.

Key Words: atherosclerosis • thiazolidinediones • lipoproteins • CD36 • peroxisome proliferator–activated receptor

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Type 2 diabetes mellitus is a major risk factor contributing to coronary heart disease (CHD), the leading cause of morbidity and mortality in developed countries.¹ The mechanisms by which diabetes promotes atherosclerosis remain obscure. Evidence suggests that the metabolic derangement frequently associated with type 2 diabetes and the insulin resistance syndrome, such as hypertension and lipoprotein abnormalities, are responsible for the increased incidence of CHD in diabetic patients.^{2 3} Prospective studies have shown that hyperinsulinemia is an independent predictor of the development not only of type 2 diabetes but also of CHD.⁴ Stout et al⁵ proposed that hyperinsulinemia directly promotes the development of atherosclerosis. However, overwhelming evidence supports the idea that hyperinsulinemia is merely a consequence of insulin resistance, which directly or indirectly enhances the development of atherosclerosis in type 2 diabetes.⁶

Thiazolidinediones (TZDs), which are novel, insulin-sensitizing agents, are increasingly used as oral hypoglycemic agents.⁷ They improve insulin sensitivity and thereby reduce hyperinsulinemia as well as hyperglycemia.^{8 9} Furthermore, troglitazone, a TZD, improves hypertension and hypertriglyceridemia, both of which represent constellations of the insulin resistance syndrome.^{10 11}

In addition to these potential indirect effects of TZDs on the risk factors of atherosclerosis, increasing evidence suggests that TZDs exert potent, direct effects on arterial wall cells. Recently, Sinohara¹² et al reported that the development of intimal lesions after balloon catheter injury in the rat aorta was significantly inhibited by troglitazone. They argued that this inhibition was mediated by troglitazone’s antimitogenic effects on vascular smooth muscle cells.¹³ It has also been reported that TZDs inhibit monocyte inflammatory cytokines,¹⁴ macrophage activation,¹⁵ and the expression of cell adhesion molecules expressed by vascular endothelial cells.^{16 17} Peroxisome proliferator–activated receptor- (PPAR-), the receptor for TZDs,¹⁸ is expressed in arterial wall cells such as vascular smooth muscle cells and macrophages.¹⁹ PPAR- may be involved in regulation of the uptake of oxidized LDL by modulating CD36, a scavenger receptor, in macrophages.^{20 21} On the basis of these results, TZDs may promote foam cell formation. However, it remains unknown whether TZDs have antiatherogenic effects.

To investigate the effects of troglitazone on fatty streak formation, the initial step of atherosclerosis, we treated apolipoprotein (apo) E–knockout mice, an animal model of atherosclerosis,²² with troglitazone and examined the resultant atherosclerotic lesions.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals
ApoE-knockout mice were a gift from Dr N. Maeda (University of North Carolina, Chapel Hill).²² These mice were back-crossed to C57BL6 mice 9 times at our facility to produce congenic animals. They were maintained on a 12-hour dark/12-hour light cycle and allowed ad libitum access to food and water. The diets used were (1) a Western-type diet (containing 0.15% cholesterol, 15% unsalted butter) and (2) a Western-type diet supplemented with 0.1% (wt/wt) troglitazone, which was a gift of Sankyo Pharmaceutical Ltd, Tokyo, Japan. Thirty-five male animals aged 5 weeks (20 as controls and 15 for the troglitazone experiments) were fed the diets for 2 months. C57BL6 mice were used for preparation of peritoneal macrophages.

Plasma Lipids, Glucose, and Insulin
After a 6-hour fast, blood was collected from the retro-orbital venous plexus.²³ Blood glucose levels were immediately measured on an Antsense II (Daikin). Plasma levels of total cholesterol (TC), triglyceride (TG), and free fatty acids (FFAs) were measured enzymatically by using Determiner TC 555, Determiner TG 555, and Determiner NEFA methods (Kyowa Medex), respectively. Pooled plasma was used for determining insulin levels with an insulin assay kit from Morinaga. Lipoprotein profiles were analyzed by high-performance liquid chromatography (HPLC) essentially as described, with some modifications.²³ In brief, 5 µL of plasma was applied to a combined column system composed of 2 TSK gel Lipopropacks (Tosoh) connected in tandem and eluted with the supplied buffer (TSK eluent LP-1, Tosoh) at a rate of 0.6 mL/min. TC concentrations in the effluents were monitored by using a kit (Determiner LTC). Areas under the elution curves for HDL peaks were determined. These values and plasma TC levels were used to calculate HDL cholesterol concentrations.

Measurement of Atherosclerotic Lesion Size
Mice were killed by cervical dislocation after blood collection. The en face surface and cross-sectional lesion areas in the aorta were determined as described previously.²³

Cell Culture
Peritoneal macrophages were prepared as described previously.²³ In brief, 1 mL of thioglycolate broth was injected into the peritoneal cavities of mice aged 3 months. After 4 days, the peritoneal cavities were lavaged with 10 mL of ice-cold saline. The cells were washed 3 times with PBS and resuspended in high-glucose Dulbecco’s modified Eagle’s medium (HG-DMEM), and 10⁶ cells were plated in 60-mm dishes (Corning). After incubation at 37°C for 2 hours, nonadherent cells were removed by washing 3 times with prewarmed PBS. The adherent cells were incubated with HG-DMEM supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (FCS, JRL Biosciences) at 37°C in an atmosphere of 5% CO₂ and 95% air. After 16 hours, the media were replaced with fresh media containing 10% (vol/vol) FCS supplemented with the indicated concentrations of troglitazone. Troglitazone was solubilized in dimethylsulfoxide (DMSO), and equivalent concentrations of DMSO were used for controls. The final concentrations of DMSO were kept at 0.1% (vol/vol).

Northern Blot Analysis
Total RNA was prepared from the aortas by use of Trizol reagent (Life Technologies, GIBCO-BRL). Twenty micrograms of RNA was subjected to electrophoresis in a 1.0% (wt/vol) agarose gel containing formalin. After transfer, the nylon membrane (Hybond N, Amersham Pharmacia Biotech) was hybridized with ³²P-labeled probes for mouse CD36, lipoprotein lipase (LPL), PPAR-, and ß-actin. cDNA polymerase chain reaction fragments were used as probes for CD36 and PPAR-. Human LPL cDNA probes were as previously described.²³

Statistics
All experimental data are expressed as mean±SD. Mean values were compared by Student’s t test and ANOVA. Spearman’s coefficients of correlation were calculated.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Plasma Glucose and Lipoproteins
Table 1 compares the body weight, blood glucose, and plasma concentrations of insulin, FFAs, and lipoprotein profiles. Fasting blood glucose levels were significantly decreased by 18.8% in the troglitazone-treated group compared with controls (P<0.05). The plasma insulin level was decreased by 52% in the troglitazone-treated group. On the other hand, there were no significant differences in either body weight or plasma FFA levels between the 2 groups. Similarly, no significant differences in plasma TC and TG levels were observed between the 2 groups. HPLC analyses revealed a selective increase in cholesterol content in a peak corresponding to HDL (Figure 1). On average, HDL cholesterol levels were increased by 74% in the troglitazone-treated group compared with controls (36±11 vs 21±10 mg/dL, P<0.05).

View this table: [in this window] [in a new window]   Table 1. Effect of Troglitazone on Body Weight, Blood Glucose, Plasma Insulin, Plasma Free Fatty Acid (FFA) Levels, and Plasma Lipids

View larger version (12K): [in this window] [in a new window]   Figure 1. Comparison of plasma lipoprotein profiles between control (A) and troglitazone-treated (B) apoE-knockout mice. ApoE-knockout mice were fed a Western-type diet with or without 0.1% troglitazone for 2 months. Pooled plasma was subjected to HPLC. Cholesterol contents in the eluates were monitored. Lipoproteins isolated by standard ultracentrifugation were used to calibrate the elution positions of chylomicron (CM), VLDL, IDL/LDL, and HDL, as indicated above the elution pattern. Note that the HDL peak was significantly elevated in the treated group compared with the control group without changing the retention time.

Atherosclerotic Lesions in the Aorta and Aortic Sinus
En face surface atherosclerotic lesions of the troglitazone-treated group were grossly smaller than those of the control group (Figures 2A and 2B). These lesions were mainly distributed on the aortic arches and the areas surrounding the branching points of the arteries. The en face surface aortic lesion area of the troglitazone group was decreased by 45% compared with the control group (6.9% vs 12.7%, P<0.05) (Figure 3A).

View larger version (86K): [in this window] [in a new window]   Figure 2. Morphology of en face surface lesions (A, B) and cross-sectional lesions (C, D) in control (A, C) and toglitazone-treated (B, D) apoE-knockout mice. ApoE-knockout mice were fed a Western-type diet with or without 0.1% troglitazone for 2 months. A representative aorta was stained for lipids with Sudan IV. Cross sections of the aortic sinus were stained with oil red O and counterstained with hematoxylin (x20).

View larger version (15K): [in this window] [in a new window]   Figure 3. Comparison of the size of en face surface (A) and cross-sectional (B) lesions between the control and troglitazone-treated groups. ApoE-knockout mice were fed a Western-type diet with or without 0.1% troglitazone for 2 months (n=10). Short lines indicate the mean±SD * P<0.05 by Student’s t test.

Microscopic examination determined that the lesions in both groups were mainly of the intermediate type, consisting of several layers of foam cells with some intracellular lipid accumulation but without a typical lipid core (Figures 2C and 2D). Typical atheromas with well-developed, lipid-rich cores and foam cell infiltration but without fibrous tissue proliferation were observed in some sections of the control group. The cross-sectional lesion areas of the troglitazone-treated group were significantly smaller (by 45%) than those of the control group (191 974±102 911 vs 351 738±175 597 µm², P<0.05) (Figure 3B).

To determine the factors mediating the antiatherosclerotic effects of troglitazone, we performed correlational analyses between lesion sizes and plasma lipid levels. When analyzed as a whole, only HDL cholesterol levels were negatively correlated with the en face lesion sizes (R=-0.54, P<0.05). When analyzed in each group, however, there was no correlation between them.

Induction of CD36 Expression in the Aorta
Figure 4 shows the results of Northern blot analysis of CD36, PPAR-, and ß-actin in the aorta. The mRNA levels of CD36 were markedly increased in the troglitazone-treated group compared with the control group (7-fold), while those of PPAR were not significantly changed.

View larger version (24K): [in this window] [in a new window]   Figure 4. Northern blot analysis of CD36 and PPAR- in the aorta. Total RNA was extracted from the aorta. Twenty micrograms of pooled samples was subjected to Northern blot analysis. ß-Actin was used as a loading control. Relative intensities of the bands for CD36 or PPAR- to those for ß-actin are indicated below each panel. CD36 expression was elevated by 7-fold, whereas the PPAR- expression was slightly elevated by 1.4-fold in response to treatment with troglitazone.

Induction of CD36 Expression in Macrophages in Culture
To determine whether troglitazone induced the expression of CD36 in vitro, peritoneal macrophages were incubated with various concentrations of troglitazone for 12 hours, and then the mRNA expression levels of CD36, LPL, PPAR-, and ß-actin were estimated by Northern blot analysis (Figure 5). Incubation with troglitazone induced a 2.5-fold increase in CD36 mRNA levels in a dose-dependent manner, whereas it increased the LPL mRNA levels by only 50% at 12 hours. Later, at 48 hours, the mRNA levels of LPL and PPAR- were also significantly induced by 20 µmol/L troglitazone (Figure 6).

View larger version (43K): [in this window] [in a new window]   Figure 5. The mRNA expression of CD36, LPL, and PPAR- in peritoneal macrophages incubated with increasing concentrations of troglitazone. Peritoneal macrophages were harvested after thioglycolate elicitation. Sixteen hours after preparation, the cells were incubated with HG-DMEM containing 10% (vol/vol) FCS supplemented with the indicated concentrations of troglitazone for 12 hours. Twenty micrograms total RNA as subjected to Northern blot analysis. ß-Actin was used as a loading control.

View larger version (46K): [in this window] [in a new window]   Figure 6. Time courses of mRNA expression of CD36, LPL, and PPAR- in peritoneal macrophages incubated with 20 µmol/L troglitazone. Peritoneal macrophages were harvested after thioglycolate elicitation. Sixteen hours after preparation, the cells were incubated with HG-DMEM containing 10% (vol/vol) FCS supplemented with 20 µmol/L troglitazone for the indicated periods. Twenty micrograms of total RNA was subjected to Northern blot analysis. ß-Actin was used as a loading control.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In the present study, we have demonstrated that troglitazone significantly inhibits the development of atherosclerotic foam cell lesions in apoE-knockout mice fed a high-fat diet. The antiatherogenic effects of troglitazone appear to be mediated, at least in part, by favorable changes in the extracellular environment: suppression of hyperinsulinemic hyperglycemia and an increase in HDL cholesterol levels. Troglitazone also strongly increased the mRNA expression of CD36 in the aorta, which is conceivably proatherogenic, according to reported observations that targeted disruption of the CD36 gene was protective against atherosclerosis.²⁴ Therefore, the CD36-increasing effects of troglitazone might be overwhelmed by the antiatherogenic effects of other factors, such as glucose and lipoproteins metabolism. The possibility remains that the other effects, which include anti-inflammation, inhibition of cell adhesion, and antioxidation, accounted for the antiatherogenic effects of troglitazone.

Troglitazone increased HDL cholesterol levels in apoE-knockout mice fed a high-fat diet (Table 1), an effect that is likely antiatherogenic. It is well established that HDL cholesterol is negatively correlated with CHD in humans.²⁵ In apoE-knockout mice that have extremely low levels of HDL cholesterol, subtle changes in this lipoprotein fraction may have profound effects on the development of atherosclerosis. For example, apoE-knockout mice that overexpress apo A-I, which results in increased HDL levels, are resistant to atherosclerosis.²⁶ Because the apo A-I gene contains a peroxisome proliferator–responsive element, it is possible that the apo A-I gene is positively regulated by PPAR- in addition to PPAR- agonists.²⁷ Furthermore, activation of PPAR- upregulates LPL gene expression.^{28 29} The increased LPL may stimulate lipolysis of TG-rich lipoproteins, thereby contributing to the elevation of plasma HDL cholesterol levels in apoE-knockout mice, as is the case with LPL-transgenic mice.²³

In addition to favorable changes in plasma lipoprotein metabolism, attenuation of hyperinsulinemic hyperglycemia, a hallmark of the insulin resistance syndrome, may underlie the antiatherogenic effects of troglitazone. Indeed, insulin has mitogenic effects on vascular smooth muscle cells.³⁰ However, it also causes vascular dilation³¹ and inhibition of platelet aggregation.³² Therefore, it is reasonable to conclude that the effects of insulin on atherosclerosis are neutral as a whole.

In contrast to changes in the extracellular environment, upregulation of CD36 mRNA in the aorta might promote atherosclerosis. CD36 is a membrane-bound molecule with diverse functions.³³ In addition to functioning as a receptor for fatty acids, CD36 mediates the uptake of oxidized LDL by macrophages as a sort of scavenger receptor.^{34 35} Although lesion size was markedly reduced in troglitazone-treated mice, the overall mRNA levels of CD36 were increased in response to treatment with troglitazone (Figure 4). Accordingly, CD36 expression in each cell should be significantly enhanced by treatment with troglitazone. In the current study, we did not precisely define which cells expressed CD36. Macrophage foam cells and endothelial cells are likely candidates. In support of this possibility, troglitazone markedly increased the mRNA expression of CD36 of macrophages in culture (Figure 5). Because CD36 is highly expressed in human atherosclerotic lesions³⁶ and its expression is enhanced by high cholesterol levels,³⁷ it has been speculated that CD36 is atherogenic. Indeed, disruption of CD36 is reportedly protective against atherosclerosis under conditions of apoE deficiency.²⁴ Therefore, we may speculate that the increased expression of CD36 stimulates the uptake of oxidized LDL, thereby promoting foam cell formation and atherosclerosis. However, troglitazone exerted apparently contradictory effects in the current experiments: protection against atherosclerosis and enhanced expression of CD36. It is possible that the antiatherogenic effects of troglitazone on other factors, such as induction of LPL and cell adhesion, overcome the proatherogenic CD36-inducing effects. Alternatively, the induction of CD36 may be protective against atherosclerosis under certain conditions. For example, it is plausible that efficient removal of denatured lipoproteins deposited in the extracellular matrixes reduces atherogenic inflammatory reactions. Further studies are needed to clarify this issue.

Currently, it is widely accepted that PPAR agonists have anti-inflammatory effects.³⁸ In particular, it has been reported that TZDs decrease the expression of cell adhesion molecules expressed by vascular endothelial cells, such as vascular cell adhesion molecule-1 and intercellular adhesion molecule-1, thereby suppressing the homing of inflammatory leukocytes, including monocytes.^{16 17} Therefore, it is conceivable that these anti-inflammatory effects of TZDs predominate over the induced expression of CD36 in macrophage foam cells. Furthermore, it is also possible that the antiatherosclerotic effects of troglitazone are, at least in part, accounted for by the effects of antioxidation due to its structural similarity to -tocopherol.³⁹

In conclusion, TZDs were shown to have protective effects against atherosclerosis in a mouse model of atherosclerosis. These effects may be mediated by the pleiotropic actions of troglitazone. Thus, TZDs are promising therapeutic agents that can be used for the prevention and/or treatment of atherosclerosis.

	Acknowledgments

 
This work was supported by a grant-in-aid for scientific research from the Ministry of Education, Science and Culture; the Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research; health sciences research grants from the Ministry of Health and Welfare; the Takeda Medical Research Foundation; the Yamanouchi Foundation for Research on Metabolic Disorders; Suzuken Memorial Foundation; and the Asahi Life Foundation. We would like to thank M. Amemiya-Kudo, T. Yoshikawa, and A.H. Hasty for comments and discussion.

Received January 13, 2000; accepted November 8, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979;241:2035–2038.[Abstract/Free Full Text]

2. Reaven G. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.[Abstract]

3. Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, Osuga J, Shionoiri F, Yahagi N, Kadowaki T, Tamemoto H, Ishibashi S, Yazaki Y, Makuuchi M. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest. 1998;101:1784–1788.[Medline] [Order article via Infotrieve]

4. Stern MP. Diabetes and cardiovascular disease: The ‘common soil’ hypothesis. Diabetes. 1995;44:369–374.[Abstract]

5. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care. 1990;13:631–654.[Abstract]

6. Jarrett RJ. Why is insulin not a risk factor for coronary heart disease? Diabetologia. 1994;37:945–947.[Medline] [Order article via Infotrieve]

7. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661–1669.[Abstract]

8. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988;37:1549–1558.[Abstract]

9. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188–1193.[Abstract/Free Full Text]

10. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism. 1993;42:75–80.[Medline] [Order article via Infotrieve]

11. Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 1994;43:1435–1439.[Abstract]

12. Shinohara E, Kihara S, Ouchi N, Funahashi T, Nakamura T, Yamashita S, Kameda-Takemura K, Matsuzawa Y. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis. 1998;136:275–279.[Medline] [Order article via Infotrieve]

13. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897–1905.[Medline] [Order article via Infotrieve]

14. Jiang C, Ting AT, Seed B. PPAR- agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–86.[Medline] [Order article via Infotrieve]

15. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation. Nature. 1998;391:79–82.[Medline] [Order article via Infotrieve]

16. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL. Peroxisome proliferator–activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19:2094–2104.[Abstract/Free Full Text]

17. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator–activated receptor- activators. Circulation. 2000;101:235–238.[Abstract/Free Full Text]

18. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR-). J Biol Chem. 1995;270:12953–12956.[Abstract/Free Full Text]

19. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor (PPAR-) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;395:7614–7619.

20. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPAR- promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241–252.[Medline] [Order article via Infotrieve]

21. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR . Cell. 1998;93:229–240.[Medline] [Order article via Infotrieve]

22. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468–471.[Abstract/Free Full Text]

23. Yagyu H, Ishibashi S, Chen Z, Osuga J, Okazaki M, Perrey S, Kitamine T, Shimada M, Ohashi K, Harada K, Shionoiri F, Yahagi N, Gotoda T, Yazaki Y, Yamada N. Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice. J Lipid Res. 1999;40:1677–1685.[Abstract/Free Full Text]

24. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049–1056.[Medline] [Order article via Infotrieve]

25. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311–1316.[Medline] [Order article via Infotrieve]

26. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899–903.

27. Staels B, Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis. 1998;137(suppl):S19–S23.

28. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPAR and PPAR activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336–5348.[Medline] [Order article via Infotrieve]

29. Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, Fievet C, Auwerx J, Staels B. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol. 1997;17:1756–1764.[Abstract/Free Full Text]

30. Capron L, Jarnet J, Kazandjian S, Housset E. Growth-promoting effects of diabetes and insulin on arteries: an in vivo study of rat aorta. Diabetes. 1986;35:973–978.[Abstract]

31. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246–2252.

32. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents: studies in vitro and in vivo. Diabetes. 1988;37:780–786.[Abstract]

33. Daviet L, McGregor JL. Vascular biology of CD36: roles of this new adhesion molecule family in different disease states. Thromb Haemost. 1997;78:65–69.[Medline] [Order article via Infotrieve]

34. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268:11811–11816.[Abstract/Free Full Text]

35. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, Nakata A, Ishigami M, Miyagawa J, Kameda-Takemura K, et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest. 1995;96:1859–1865.

36. Nakata A, Nakagawa Y, Nishida M, Nozaki S, Miyagawa J, Nakagawa T, Tamura R, Matsumoto K, Kameda-Takemura K, Yamashita S, Matsuzawa Y. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol. 1999;19:1333–1339.[Abstract/Free Full Text]

37. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AMJ, Hajjar DP, Nicholson AC. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-. J Lipid Res. 2000;41:688–696.[Abstract/Free Full Text]

38. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor- activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10:245–257.[Medline] [Order article via Infotrieve]

39. Noguchi N, Sakai H, Kato Y, Tsuchiya J, Yamamoto Y, Niki E, Horikoshi H, Kodama T. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis. 1996;123:227–234. [Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				J. M. Kleinhenz, D. J. Kleinhenz, S. You, J. D. Ritzenthaler, J. M. Hansen, D. R. Archer, R. L. Sutliff, and C. M. Hart Disruption of endothelial peroxisome proliferator-activated receptor-{gamma} reduces vascular nitric oxide production Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1647 - H1654. [Abstract] [Full Text] [PDF]

				H. Nakaya, B. D. Summers, A. C. Nicholson, A. M. Gotto Jr., D. P. Hajjar, and J. Han Atherosclerosis in LDLR-Knockout Mice Is Inhibited, but Not Reversed, by the PPAR{gamma} Ligand Pioglitazone Am. J. Pathol., June 1, 2009; 174(6): 2007 - 2014. [Abstract] [Full Text] [PDF]

				S. Yasuda, H. Kobayashi, M. Iwasa, I. Kawamura, S. Sumi, B. Narentuoya, T. Yamaki, H. Ushikoshi, K. Nishigaki, K. Nagashima, et al. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-{gamma} receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1558 - H1565. [Abstract] [Full Text] [PDF]

				D. F. Lehmann and B. B. Lohray A Lesson in Moderation: Applying Pharmacodynamics to Clarify the Relationship Between Thiazolidinediones and Adverse Vascular Outcomes in Type 2 Diabetes J. Clin. Pharmacol., August 1, 2008; 48(8): 999 - 1002. [Full Text] [PDF]

				E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1050 - 1059. [Abstract] [Full Text] [PDF]

				M. Davidson, P. M. Meyer, S. Haffner, S. Feinstein, R. D'Agostino Sr, G. T. Kondos, A. Perez, Z. Chen, and T. Mazzone Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus Circulation, April 22, 2008; 117(16): 2123 - 2130. [Abstract] [Full Text] [PDF]

				S. Z. Duan, M. G. Usher, and R. M. Mortensen Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature Circ. Res., February 15, 2008; 102(3): 283 - 294. [Abstract] [Full Text] [PDF]

				E. Thorp, G. Kuriakose, Y. M. Shah, F. J. Gonzalez, and I. Tabas Pioglitazone Increases Macrophage Apoptosis and Plaque Necrosis in Advanced Atherosclerotic Lesions of Nondiabetic Low-Density Lipoprotein Receptor Null Mice Circulation, November 6, 2007; 116(19): 2182 - 2190. [Abstract] [Full Text] [PDF]

				B. Gustafson, A. Hammarstedt, C. X. Andersson, and U. Smith Inflamed Adipose Tissue: A Culprit Underlying the Metabolic Syndrome and Atherosclerosis Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2276 - 2283. [Abstract] [Full Text] [PDF]

				C. Werner, C. H. Kamani, C. Gensch, M. Bohm, and U. Laufs The Peroxisome Proliferator Activated Receptor-{gamma} Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance Diabetes, October 1, 2007; 56(10): 2609 - 2615. [Abstract] [Full Text] [PDF]

				S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]

				J. T. Crossno Jr., C. V. Garat, J. E. B. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, and D. J. Klemm Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L885 - L897. [Abstract] [Full Text] [PDF]

				T. Mazzone, P. M. Meyer, S. B. Feinstein, M. H. Davidson, G. T. Kondos, R. B. D'Agostino Sr, A. Perez, J.-C. Provost, and S. M. Haffner Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial JAMA, December 6, 2006; 296(21): 2572 - 2581. [Abstract] [Full Text] [PDF]

				L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O'Rahilly, et al. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors Pharmacol. Rev., December 1, 2006; 58(4): 726 - 741. [Abstract] [Full Text] [PDF]

				R. Avallone, A. Demers, A. Rodrigue-Way, K. Bujold, D. Harb, S. Anghel, W. Wahli, S. Marleau, H. Ong, and A. Tremblay A Growth Hormone-Releasing Peptide that Binds Scavenger Receptor CD36 and Ghrelin Receptor Up-Regulates Sterol Transporters and Cholesterol Efflux in Macrophages through a Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Pathway Mol. Endocrinol., December 1, 2006; 20(12): 3165 - 3178. [Abstract] [Full Text] [PDF]

				C. B Patle, J. A De Lemos, K. L Wyne, and D. K McGuire Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR{gamma} agonism Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 65 - 71. [Abstract] [PDF]

				H. Kosuge, G. Haraguchi, N. Koga, Y. Maejima, J.-i. Suzuki, and M. Isobe Pioglitazone Prevents Acute and Chronic Cardiac Allograft Rejection Circulation, June 6, 2006; 113(22): 2613 - 2622. [Abstract] [Full Text] [PDF]

				A. Ghazalpour, X. Wang, A. J. Lusis, and M. Mehrabian Complex Inheritance of the 5-Lipoxygenase Locus Influencing Atherosclerosis in Mice Genetics, June 1, 2006; 173(2): 943 - 951. [Abstract] [Full Text] [PDF]

				C. R. Benton, D. P. Y. Koonen, J. Calles-Escandon, N. N. Tandon, J. F. C. Glatz, J. J. F. P. Luiken, J. J. Heikkila, and A. Bonen Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle J. Physiol., May 15, 2006; 573(1): 199 - 210. [Abstract] [Full Text] [PDF]

				K. Esposito, M. Ciotola, D. Carleo, B. Schisano, F. Saccomanno, F. C. Sasso, D. Cozzolino, R. Assaloni, D. Merante, A. Ceriello, et al. Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome Diabetes Care, May 1, 2006; 29(5): 1071 - 1076. [Abstract] [Full Text] [PDF]

				S. Lim, C. J. Jin, M. Kim, S. S. Chung, H. S. Park, I. K. Lee, C. T. Lee, Y. M. Cho, H. K. Lee, and K. S. Park PPAR{gamma} Gene Transfer Sustains Apoptosis, Inhibits Vascular Smooth Muscle Cell Proliferation, and Reduces Neointima Formation After Balloon Injury in Rats Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 808 - 813. [Abstract] [Full Text] [PDF]

				A. Munteanu, M. Taddei, I. Tamburini, E. Bergamini, A. Azzi, and J.-M. Zingg Antagonistic Effects of Oxidized Low Density Lipoprotein and {alpha}-Tocopherol on CD36 Scavenger Receptor Expression in Monocytes: INVOLVEMENT OF PROTEIN KINASE B AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-{gamma} J. Biol. Chem., March 10, 2006; 281(10): 6489 - 6497. [Abstract] [Full Text] [PDF]

				G. D. Barish Peroxisome Proliferator-Activated Receptors and Liver X Receptors in Atherosclerosis and Immunity J. Nutr., March 1, 2006; 136(3): 690 - 694. [Abstract] [Full Text] [PDF]

				F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 28 - 40. [Abstract] [Full Text] [PDF]

				S Soumian, R Gibbs, A Davies, and C Albrecht mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease J. Clin. Pathol., December 1, 2005; 58(12): 1255 - 1260. [Abstract] [Full Text] [PDF]

				A. C. Calkin, J. M. Forbes, C. M. Smith, M. Lassila, M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1903 - 1909. [Abstract] [Full Text] [PDF]

				J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart Peroxisome Proliferator-Activated Receptor {gamma} Ligands Stimulate Endothelial Nitric Oxide Production Through Distinct Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Mechanisms Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1810 - 1816. [Abstract] [Full Text] [PDF]

				V. R. Babaev, P. G. Yancey, S. V. Ryzhov, V. Kon, M. D. Breyer, M. A. Magnuson, S. Fazio, and M. F. Linton Conditional Knockout of Macrophage PPAR{gamma}Increases Atherosclerosis in C57BL/6 and Low-Density Lipoprotein Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1647 - 1653. [Abstract] [Full Text] [PDF]

				M.R. Langenfeld, T. Forst, C. Hohberg, P. Kann, G. Lubben, T. Konrad, S.D. Fullert, C. Sachara, and A. Pfutzner Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study Circulation, May 17, 2005; 111(19): 2525 - 2531. [Abstract] [Full Text] [PDF]

				M. H. Clough, D. J. Schneider, B. E. Sobel, M. F. White, M. P. Wadsworth, and D. J. Taatjes Attenuation of Accumulation of Neointimal Lipid by Pioglitazone in Mice Genetically Deficient in Insulin Receptor Substrate-2 and Apolipoprotein E J. Histochem. Cytochem., May 1, 2005; 53(5): 603 - 610. [Abstract] [Full Text] [PDF]

				A. H. Xiang, R. K. Peters, S. L. Kjos, C. Ochoa, A. Marroquin, J. Goico, S. Tan, C. Wang, S. P. Azen, C.-r. Liu, et al. Effect of Thiazolidinedione Treatment on Progression of Subclinical Atherosclerosis in Premenopausal Women at High Risk for Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1986 - 1991. [Abstract] [Full Text] [PDF]

				L. Makowski, K. C. Brittingham, J. M. Reynolds, J. Suttles, and G. S. Hotamisligil The Fatty Acid-binding Protein, aP2, Coordinates Macrophage Cholesterol Trafficking and Inflammatory Activity: MACROPHAGE EXPRESSION OF aP2 IMPACTS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma} AND I{kappa}B KINASE ACTIVITIES J. Biol. Chem., April 1, 2005; 280(13): 12888 - 12895. [Abstract] [Full Text] [PDF]

				M. Vinals, I. Bermudez, G. Llaverias, M. Alegret, R. M. Sanchez, M. Vazquez-Carrera, and J. C. Laguna Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages Cardiovasc Res, April 1, 2005; 66(1): 141 - 149. [Abstract] [Full Text] [PDF]

				S. Redondo, E. Ruiz, C. G. Santos-Gallego, E. Padilla, and T. Tejerina Pioglitazone Induces Vascular Smooth Muscle Cell Apoptosis Through a Peroxisome Proliferator-Activated Receptor-{gamma}, Transforming Growth Factor-{beta}1, and a Smad2-Dependent Mechanism Diabetes, March 1, 2005; 54(3): 811 - 817. [Abstract] [Full Text] [PDF]

				F. J. Schopfer, Y. Lin, P. R. S. Baker, T. Cui, M. Garcia-Barrio, J. Zhang, K. Chen, Y. E. Chen, and B. A. Freeman Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor {gamma} ligand PNAS, February 15, 2005; 102(7): 2340 - 2345. [Abstract] [Full Text] [PDF]

				C. Knouff and J. Auwerx Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology Endocr. Rev., December 1, 2004; 25(6): 899 - 918. [Abstract] [Full Text] [PDF]

				A. C. Li and C. K. Glass PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis J. Lipid Res., December 1, 2004; 45(12): 2161 - 2173. [Abstract] [Full Text] [PDF]

				L. Ragolia, T. Palaia, T. B. Koutrouby, and J. K. Maesaka Inhibition of cell cycle progression and migration of vascular smooth muscle cells by prostaglandin D2 synthase: resistance in diabetic Goto-Kakizaki rats Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1273 - C1281. [Abstract] [Full Text] [PDF]

				K. Z. Al-Shali, A. A. House, A. J.G. Hanley, H. M.R. Khan, S. B. Harris, B. Zinman, M. Mamakeesick, A. Fenster, J. D. Spence, and R. A. Hegele Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor {gamma} Associated With Carotid Atherosclerosis Stroke, September 1, 2004; 35(9): 2036 - 2040. [Abstract] [Full Text] [PDF]

				H. L. Keen, M. J. Ryan, A. Beyer, S. Mathur, T. E. Scheetz, B. D. Gackle, F. M. Faraci, T. L. Casavant, and C. D. Sigmund Gene expression profiling of potential PPAR{gamma} target genes in mouse aorta Physiol Genomics, June 17, 2004; 18(1): 33 - 42. [Abstract] [Full Text] [PDF]

				R. Cunard, Y. Eto, J. T. Muljadi, C. K. Glass, C. J. Kelly, and M. Ricote Repression of IFN-{gamma} Expression by Peroxisome Proliferator-Activated Receptor {gamma} J. Immunol., June 15, 2004; 172(12): 7530 - 7536. [Abstract] [Full Text] [PDF]

				S. E. Epstein, E. Stabile, T. Kinnaird, C. W. Lee, L. Clavijo, and M. S. Burnett Janus Phenomenon: The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis Circulation, June 15, 2004; 109(23): 2826 - 2831. [Full Text] [PDF]

				B. Desvergne, L. Michalik, and W. Wahli Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the Road Mol. Endocrinol., June 1, 2004; 18(6): 1321 - 1332. [Abstract] [Full Text] [PDF]

				K. S. Meir and E. Leitersdorf Atherosclerosis in the Apolipoprotein E-Deficient Mouse: A Decade of Progress Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1006 - 1014. [Abstract] [Full Text] [PDF]

				N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]

				J. S. Sidhu, Z. Kaposzta, H. S. Markus, and J. C. Kaski Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes Mellitus Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 930 - 934. [Abstract] [Full Text]

				M. Ricote, A. F. Valledor, and C. K. Glass Decoding Transcriptional Programs Regulated by PPARs and LXRs in the Macrophage: Effects on Lipid Homeostasis, Inflammation, and Atherosclerosis Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 230 - 239. [Abstract] [Full Text]

				Y. Lin, X. Zhu, F. L. Mclntee, H. Xiao, J. Zhang, M. Fu, and Y. E. Chen Interferon Regulatory Factor-1 Mediates PPAR{gamma}-Induced Apoptosis in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 257 - 263. [Abstract] [Full Text]

				W. A. Hsueh and D. Bruemmer Peroxisome Proliferator-Activated Receptor {gamma}: Implications for Cardiovascular Disease Hypertension, February 1, 2004; 43(2): 297 - 305. [Abstract] [Full Text] [PDF]

				K. E. Watson, A. L. Peters Harmel, and G. Matson Atherosclerosis in Type 2 Diabetes Mellitus: The Role of Insulin Resistance Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 253 - 260. [Abstract] [PDF]

				J. J. Bright, C. Natarajan, G. Muthian, Y. Barak, and R. M. Evans Peroxisome Proliferator-Activated Receptor-{gamma}-Deficient Heterozygous Mice Develop an Exacerbated Neural Antigen-Induced Th1 Response and Experimental Allergic Encephalomyelitis J. Immunol., December 1, 2003; 171(11): 5743 - 5750. [Abstract] [Full Text] [PDF]

				E. K. Ceaser, A. Ramachandran, A.-L. Levonen, and V. M. Darley-Usmar Oxidized low-density lipoprotein and 15-deoxy-{Delta}12,14-PGJ2 increase mitochondrial complex I activity in endothelial cells Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2298 - H2308. [Abstract] [Full Text] [PDF]

				J. S. Sidhu, D. Cowan, and J.-C. Kaski The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1757 - 1763. [Abstract] [Full Text] [PDF]

				L. Ragolia, T. Palaia, E. Paric, and J. K. Maesaka Prostaglandin D2 Synthase Inhibits the Exaggerated Growth Phenotype of Spontaneously Hypertensive Rat Vascular Smooth Muscle Cells J. Biol. Chem., June 6, 2003; 278(24): 22175 - 22181. [Abstract] [Full Text] [PDF]

				C. J. Lyon, R. E. Law, and W. A. Hsueh Minireview: Adiposity, Inflammation, and Atherogenesis Endocrinology, June 1, 2003; 144(6): 2195 - 2200. [Abstract] [Full Text] [PDF]

				C.-H. Lee, P. Olson, and R. M. Evans Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors Endocrinology, June 1, 2003; 144(6): 2201 - 2207. [Abstract] [Full Text] [PDF]

				K. T. Iida, Y. Kawakami, M. Suzuki, H. Shimano, H. Toyoshima, H. Sone, K. Shimada, Y. Iwama, Y. Watanabe, H. Mokuno, et al. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1125 - E1130. [Abstract] [Full Text] [PDF]

				J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass PPAR{gamma} and PPAR{delta} negatively regulate specific subsets of lipopolysaccharide and IFN-{gamma} target genes in macrophages PNAS, May 27, 2003; 100(11): 6712 - 6717. [Abstract] [Full Text] [PDF]

				M. Abe, K. Hasegawa, H. Wada, T. Morimoto, T. Yanazume, T. Kawamura, M. Hirai, Y. Furukawa, and T. Kita GATA-6 Is Involved in PPAR{gamma}-Mediated Activation of Differentiated Phenotype in Human Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 404 - 410. [Abstract] [Full Text] [PDF]

				C.A. Argmann, C.G. Sawyez, C.J. McNeil, R.A. Hegele, and M.W. Huff Activation of Peroxisome Proliferator-Activated Receptor Gamma and Retinoid X Receptor Results in Net Depletion of Cellular Cholesteryl Esters in Macrophages Exposed to Oxidized Lipoproteins Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 475 - 482. [Abstract] [Full Text] [PDF]

				R. Cunard, D. DiCampli, D. C. Archer, J. L. Stevenson, M. Ricote, C. K. Glass, and C. J. Kelly WY14,643, a PPAR{alpha} Ligand, Has Profound Effects on Immune Responses In Vivo J. Immunol., December 15, 2002; 169(12): 6806 - 6812. [Abstract] [Full Text] [PDF]

				M. Ishibashi, K. Egashira, K.-i. Hiasa, S. Inoue, W. Ni, Q. Zhao, M. Usui, S. Kitamoto, T. Ichiki, and A. Takeshita Antiinflammatory and Antiarteriosclerotic Effects of Pioglitazone Hypertension, November 1, 2002; 40(5): 687 - 693. [Abstract] [Full Text] [PDF]

				X. Wang and B. Paigen Quantitative Trait Loci and Candidate Genes Regulating HDL Cholesterol: A Murine Chromosome Map Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1390 - 1401. [Abstract] [Full Text] [PDF]

				J. Han, D. P. Hajjar, X. Zhou, A. M. Gotto Jr., and A. C. Nicholson Regulation of Peroxisome Proliferator-activated Receptor-gamma -mediated Gene Expression. A NEW MECHANISM OF ACTION FOR HIGH DENSITY LIPOPROTEIN J. Biol. Chem., June 21, 2002; 277(26): 23582 - 23586. [Abstract] [Full Text] [PDF]

				C. S. Elangbam, T. A. Brodie, H. Roger Brown, J. B. Nold, T. J. Raczniak, R. D. Tyler, R. M. Lightfoot, and H. G. Wall Vascular Effects of GI262570X (PPAR-{gamma} agonist) in the Brown Adipose Tissue of Han Wistar Rats: A Review of 1-month, 13-week, 27-week and 2-year Oral Toxicity Studies Toxicol Pathol, June 1, 2002; 30(4): 420 - 426. [Abstract] [PDF]

				O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 717 - 726. [Abstract] [Full Text] [PDF]

				N. Marx, B. Kehrle, K. Kohlhammer, M. Grub, W. Koenig, V. Hombach, P. Libby, and J. Plutzky PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis Circ. Res., April 5, 2002; 90(6): 703 - 710. [Abstract] [Full Text] [PDF]

				R. Cunard, M. Ricote, D. DiCampli, D. C. Archer, D. A. Kahn, C. K. Glass, and C. J. Kelly Regulation of Cytokine Expression by Ligands of Peroxisome Proliferator Activated Receptors J. Immunol., March 15, 2002; 168(6): 2795 - 2802. [Abstract] [Full Text] [PDF]

				L. L. Demer Adipose Rex: Fat and Fats That Rule Differentiation Circ. Res., February 22, 2002; 90(3): 241 - 243. [Full Text] [PDF]

				Y. Oyama, N. Akuzawa, R. Nagai, and M. Kurabayashi PPAR{gamma} Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 Cells Circ. Res., February 22, 2002; 90(3): 348 - 355. [Abstract] [Full Text] [PDF]

				R. Walczak and P. Tontonoz PPARadigms and PPARadoxes: expanding roles for PPAR{gamma} in the control of lipid metabolism J. Lipid Res., February 1, 2002; 43(2): 177 - 186. [Abstract] [Full Text] [PDF]

				B. Staels The clinical significance of PPAR{alpha} and {gamma} agonism The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1_suppl): S28 - S31. [Abstract] [PDF]

				H. R. Davis Jr, D. S. Compton, L. Hoos, and G. Tetzloff Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in ApoE Knockout Mice Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 2032 - 2038. [Abstract] [Full Text] [PDF]

				Y. Oyama, N. Akuzawa, R. Nagai, and M. Kurabayashi PPAR{gamma} Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 Cells Circ. Res., February 22, 2002; 90(3): 348 - 355. [Abstract] [Full Text] [PDF]

				N. Marx, B. Kehrle, K. Kohlhammer, M. Grub, W. Koenig, V. Hombach, P. Libby, and J. Plutzky PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis Circ. Res., April 5, 2002; 90(6): 703 - 710. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, Z. Articles by Yamada, N. Search for Related Content PubMed PubMed Citation Articles by Chen, Z. Articles by Yamada, N. Related Collections Cardiovascular Pharmacology Gene expression Genetically altered mice Type 2 diabetes Lipid and lipoprotein metabolism